The Biological Operating System of Life: BioOS™

We made our discoveries by testing the hypothesis that living organisms contain code that controls files – an operating system. We assume that the genome is the code. Our technology is centered on the idea that RNA is both code and files.

The disease-specific RNA biomarkers that we have discovered are chronically expressed. The RNA sequences homologous to our proprietary database are biomarkers for neurologic diseases with very strong signal to noise.

Workflow

Fitting Right Into Current Lab Workflows

Product Demonstration

AACC Annual Meeting 2021

FBB Biomed Technology Featured Again at AACC Annual Meeting

RNA vs. DNA Diagnostics

RNA offers two key advantages over DNA: First, it is far more abundant than DNA in human tissue, which means it is easier to build more accurate diagnostics due to higher nucleic acid yield.

Second, due to RNA’s functional and regulatory role in molecular processes, RNA makes real-time diagnostics possible, while DNA only allows for risk stratification.

RNA Technology

The advancement of sequencing hardware and bioinformatic software has enabled the discovery and utilization of ribonucleic acid (RNA) for diagnostic purposes.

We use a combination of proprietary sample enrichment and bioinformatic analysis to filter out and measure our FBB Biomed RNA biomarkers for neurologic diseases.

Research

Proof-of-Concept Studies

Background: Using the expression of disease-specific RNA biomarkers in RRMS patients to enable a differential diagnosis for RRMS

Publication #1: T. Wahls, M. Chimenti, J. Kamholz, and H. Urnovitz. (2020, May). “RNA Differential Expression In Serial Blood Samples Of Relapsing Remitting Multiple Sclerosis Patients Correlates With Clinically Reported Flares.” MULTIPLE SCLEROSIS JOURNAL, Vol. 26, No. 1_ SUPPL, pp. 81-81. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2020.

Publication #2: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.

RNA biomarkers over-expressed: Yes

Potential drug targets detected: Yes

Background: Using the expression of disease-specific RNA biomarkers in PD patients to enable a differential diagnosis for PD

Publication: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.

RNA biomarkers over-expressed: Yes

Potential drug targets detected: Yes

Background: Using the expression of disease-specific RNA biomarkers in AD patients to enable a differential diagnosis for AD

Publication: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.

RNA biomarkers over-expressed: Yes

Potential drug targets detected: Yes